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ABSTRACT: The measurement of receptor occupancy (RO) using positron emission 
tomography (PET) has been instrumental in guiding discovery and development of CNS directed 
therapeutics. We and others have investigated muscarinic acetylcholine receptor 4 (M4) positive 
allosteric modulators (PAMs) for the treatment of symptoms associated with neuropsychiatric 
disorders. In this article, we describe the synthesis, in vitro, and in vivo characterization of a 
series of central pyridine-related M4 PAMs that can be conveniently radiolabeled with carbon-11 
as PET tracers for the in vivo imaging of an allosteric binding site of the M4 receptor. We first 
demonstrated its feasibility by mapping the receptor distribution in mouse brain and confirming 
that a lead molecule 1 binds selectively to the receptor only in the presence of the orthosteric 
agonist carbachol.  Through a competitive binding affinity assay and a number of 
physiochemical properties filters, several related compounds were identified as candidates for in 
vivo evaluation.  These candidates were then radiolabeled with 11C and studied in vivo in rhesus 
monkeys. This research eventually led to the discovery of the clinical radiotracer candidate 
[11C]MK-6884. 
INTRODUCTION  
There were an estimated 46.8 million people worldwide living with dementia in 2015 and 
this number is believed to have grown to 50 million people in 2017.1 Alzheimer’s disease (AD) 
is the major cause of dementia in the elderly.2 While progressive cognitive decline is a hallmark 
 
symptom of dementia, the condition is also strongly associated with psychiatric and behavioral 
symptoms such as hallucinations, delusions, persistent aggression, severe agitation, and risk of 
harming others. These behavioral symptoms are the main drivers for institutionalization.3 
Currently, there is a significant unmet medical need for efficacious and safe drugs to alleviate 
behavioral disturbances in these patients.3   
Muscarinic acetylcholine receptors (mAChR) are members of the G protein-coupled 
receptor superfamily that mediates the actions of the neurotransmitter acetylcholine in both the 
central and peripheral nervous system.4 Five distinct muscarinic receptors (M1-M5) have been 
identified in mammals. In the central nervous system (CNS), these receptors play a critical role in 
mediating higher cognitive processing and control of dopamine release.4 Clinical studies with 
xanomeline, an M1/M4 preferring agonist, have demonstrated that stimulating the muscarinic 
cholinergic system is a viable treatment for alleviating psychosis and behavioral disturbances in 
AD and schizophrenia patients.5–10 However, xanomeline, like other muscarinic agonists, failed 
in further clinical development due to an intolerable adverse side effect profile, presumably 
resulting from a lack of adequate receptor subtype selectivity.11–14  The M4 muscarinic 
acetylcholine receptor is predominantly expressed in the striatum, as well as in the hippocampus 
and cortex.15 It has been implicated in several CNS disorders.16 Preclinical experiments identified 
the M4 receptor as the mAChR subtype responsible for antipsychotic-like efficacy as well as 
modest cognitive enhancement.17 M4 positive allosteric modulators are anticipated to provide a 
greater opportunity for target selectivity compared to an orthosteric agonist, as they bind to a site 
that is distinct from that of the endogenous ligand. This feature may translate to an improved 
clinical safety and tolerability profile.17–25 Moreover, allosteric modulation may offer potential 
 
advantages such as maintaining both spatial and temporal neurotransmission through modulation 
of physiologically relevant receptor-mediated neural signaling pathways.17-25   
Noninvasive imaging of M4 PAMs using positron emission tomography (PET) allows 
quantification of the distribution, expression, and modulation of this receptor under physiological 
and pathological conditions. With a validated PET ligand to the receptor, PET can be used to 
assess receptor occupancy (RO) of a drug candidate at the same receptor, thereby defining its 
pharmacodynamic profile and identifying therapeutically relevant dose ranges. In general, the 
PET tracer should provide high specific signal (total/non-specific ≥ 1.5:1) to allow the 
quantitative mapping of the target of interest. It should have in vivo displaceable binding suitable 
to determine pharmacokinetics (PK)/RO relationships in preclinical species and humans. In vitro 
binding potential (BPND), defined as the ratio of available receptor sites (Bmax) to the equilibrium 
distribution constant (Kd), should be > 10 in the highest receptor density region. In addition, the 
chemical structure of the tracer should be amenable to radionuclide incorporation (11C, 18F) using 
routes that can be reliably executed at clinical PET centers. To realize these goals, the tracer 
should have the following properties: high permeability (Papp > 20 x 10
-6 cm/s), non-substrate of 
efflux transporters such as P-glycoprotein (P-gp) (transport ratio < 2), and low to moderate 
lipophilicity (shake-flask Log D < 3.5) to avoid high non-specific binding. 26, 27  
We previously communicated the discovery of a lead series exemplified by compound 1 
(Figure 1), a potent M4 PAM with adequate mAChR subtype selectivity over the other 
muscarinic receptors subtypes.28 To support the concurrent discovery program aiming at the 
identification of a suitable M4 PAM for clinical development, we started a research program to 
develop a PET tracer for in vivo imaging of the M4 allosteric binding site in brain.  In this 
 
article, we describe the work leading to the identification of an M4 PAM PET tracer, [11C]MK-
6884 (13).29  
 
 
Figure 1. Compound 1,28 [3H]1, [11C]1 
 
RESULTS AND DISCUSSION   
 The tritium-labeled analog of 1 (Figure 1) provided us with a good starting point 
to study the feasibility of developing an allosteric M4 PET tracer and to explore the relationship 
between receptor binding and function, as it is an M4 PAM ligand with high affinity (Ki = 3.1 
nM) and good physicochemical properties (sF logD = 2.5). Our discovery efforts began with 
mapping M4 receptor distribution, concentration (Bmax), binding specificity, and selectivity. 
First, autoradiography was performed using 5 nM of [3H]1 in brain tissue from wild type (WT) 
and M4 knock out (KO) mice in the presence of 10 M carbachol, a stable orthosteric mAChR 
agonist (Figure 2). The highest binding density was found in mouse brain striatum (135 optical 
density or O.D. units), moderate binding in cortex (36 O.D. units) and thalamus (25 O.D. units), 
 
and negligible displaceable binding in cerebellum (< 10 O.D. units). Minimal binding in all 
regions was observed in the absence of carbachol. Minimal binding was also observed in the 
presence of carbachol in brain tissue from M4 KO mice. The results demonstrated that binding of 
[3H]1 is dependent on the presence of an orthosteric agonist and M4 specific (Figure 2).   
 
 
Figure 2. Upper panels: total binding of [3H]1 in mouse brain slices by in vitro autoradiography. 
Lower panels: non-displaceable binding was defined with unlabeled 1 (2 µM). 
 In rhesus monkey and human brain tissue homogenates, saturation binding studies show 
that [3H]1 binds to a single, saturable site, as determined by a non-linear curve fit (Figure 3). The 
Kd and Bmax values of [
3H]1 in monkey and human striatum tissue are shown in Table 1.  The 
density of M4 receptors is low (<10 nM) in monkey and human, and while the Kd value for [
3H]1 
is moderate, the affinity is not sufficient to achieve a Bmax/Kd ratio greater than 10. Subsequently, 
compound 1 was radiolabeled with [11C]methyl iodide and studied in vivo in rhesus monkey to 
evaluate brain uptake and specific binding to the M4 PAM binding site. As expected, based on 
the binding affinity (Kd), [
11C]1 did not show specific signal, despite having appropriate 
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Figure 3. Scatchard analysis of saturation binding studies with[3H]1 in a) rhesus monkey 
striatum homogenates; b) human striatum homogenates. 
 
Table 1. Bmax and Kd values for [
3H]1 in rhesus monkey and human striatum measured in the 
presence of 10 M carbachol 
 Kd (nM) Bmax (nM) 
Rhesus monkey striatuma 12.8  7.7 
Human striatumb 17.6 7.2 
a) average of two determinations; b) single determination 
 We hypothesized that further improvement in binding affinity was necessary, while 
maintaining optimal physicochemical properties. We started by identifying analogs that are 
amenable to radiolabeling and potent against M4 PAM, as measured by FLIPR.  We then 
selected these analogs for measurement of M4 binding affinity (Ki), which was determined using 
competition binding of M4 allosteric analogs (in the presence of 10 µM ACh) at human M4 
receptors expressed in Chinese hamster ovary (CHO) cells with [3H]1. Table 2 lists compounds 





























with fixed R6 methyl substitution on the central pyridine ring. Using compound 1 as a starting 
point, we first altered the tail group R3 off the nitrogen of pyrazole while keeping the R2 lactam 
group constant.  Methyl substitution on the tertiary position of the cyclopentyl group improved 
binding affinity (compound 2; Ki = 1.0 nM) compared to the fluoro-substituted compound 1 (Ki 
= 3.1 nM).  An open carbo-chain tail was detrimental to the binding affinity (compound 3; Ki = 
9.8 nM).  Distal fluoro-substitution on the cyclopentyl group also decreased the binding affinity 
(compound 4; Ki = 15 nM) when compared to the unsubstituted cyclopentyl compound 5 (Ki = 
2.9 nM).  A bridged [1.1.1] bicyclic group also decreased the binding affinity slightly to 5.2 nM 
(compound 6), while a cyclohexyl group with bis-fluoro-substitution at the 4-position further 
reduced the binding affinity with a Ki of 14 nM (compound 7). A cyclopropyl ring as the tail 
group is also unsuitable for improving the affinity (compound 8) as Ki dramatically increases to 
30 nM.  From this exercise, we concluded that a 5-membered ring system was optimal for M4 
binding affinity.  
Next, we screened a small number of R2 substitutions on the pyridine ring that would 
allow for radiolabeling. Methoxycinnoline as R2 combined with (methylcyclopentyl)methyl 
group as R3 improved the binding affinity into the sub-nanomolar range (compound 9, Ki = 0.6 
nM).  However, substituting the methoxy group in the cinnoline with the dimethylamino group 
failed to improve binding affinity (compound 10, Ki = 4.9 nM). Another functional group, 2-
methyl indazole, also showed detrimental effect on binding Ki as demonstrated by compound 11 
with a Ki = 13 nM.   
 
Table 2. FLIPR assay results and Ki of M4 PAMs: R2 and R3 variations  
 
 













































































a) Calcium mobilization FLIPR assays, IP values represent the geometric average of at least two experiments. b) 
The maximal efficacy normalized to the maximal efficacy of human ACh ranged from 90 to 109% for compounds 1 
– 10, and 80% for compound 11. c) Competition binding Ki using [3H]1, values represent the geometric average of at 
least two experiments. d) n = 1, single number in italics; n = 2, geometric mean reported, the italicized values in 
parentheses represent the two measurements; n > 2, geometric mean reported, the values in parentheses represent the 
lower and upper limits of the 95% confidence intervals. e) racemic isomers with trans stereochemistry. 
  
Next, we investigated R4, R5 and R6 substitutions on the central pyridine ring by fixing 
the R2 group as the methyl lactam and the tail group on pyrazole (R3) as the 
(methylcyclopentyl)methyl.  The data are summarized in Table 3.  When all three positions were 
unsubstituted, the binding affinity decreased to a Ki of 10 nM (compound 12).  Cyano-
substitution at the 4- and 6-positions were examined, with 6-substituted cyano showing 
significant improvement in Ki (13, Ki = 0.2 nM) and 4-substituted cyano compound 16 
displaying decreased binding affinity (Ki = 22 nM).  Therefore, 6-cyano substitution was 
preferred over methyl for binding affinity (compound 13 vs. compound 2).  The preference of 
substitution on 5- and 6- positions was examined by fluorine atom in compound 14 and 
compound 15, with substitution at the 6-position preferred (compound 14, Ki = 1.5 nM; 
compound 15, Ki = 7.5 nM).  Bis-substitutions were also investigated in compounds 17–19, 
which demonstrated similar Ki’s as compound 2.  A methyl fluoro group at the 6-position 
combined with 5-fluoro in compound 19 provided an alternative labeling handle (18F).  However, 
this combination did not show any advantage in terms of binding affinity.  When the 5-position 
and 6-position were fused to make a cyclopentanone ring, the binding affinity improved 
significantly, as evident from compound 20 with a Ki of 0.2 nM.   
 
 
Table 3. FLIPR assay and Ki of M4 PAM core substitutions 
  
Compound R6 R5 R4 
hM4 FLIPR IP 
(nM)a,b,d 
Ki (nM)c,d 




















































a) Calcium mobilization FLIPR assays, IP values represent the numerical average of at least two experiments. b) 
The maximal efficacy normalized to the maximal efficacy of human ACh ranged from 83 to 101% except for 74% 
for compound 15 and 52% for compound 20. c) Competition binding Ki using [3H]1, values represent the numerical 
average of at least two experiments. d) n = 1, single number in italics; n = 2, geometric mean reported, the italicized 
values in parentheses represent the two measurements; n > 2, geometric mean reported, the values in parentheses 
represent the lower and upper limits of the 95% confidence intervals.  
  
Compound 13 exhibited promising affinity, and the R6 cyano substituent could be used to 
incorporate an 11C label. This approach provided an opportunity to investigate a wider variety of 
R2 groups. Several additional bicyclic ring systems were examined and summarized in Table 4. 
Imidazopyridine exhibited reduced binding affinity compared to the lactam (compound 21, Ki = 
3.8 nM vs. compound 13, Ki = 0.2 nM). Promisingly, R2 azacycles displayed subnano molar 
binding affinity (compounds 22–25).  The R2 azacycles in compounds 22, 23 and 25 were 6,5-
fused bicyclic systems and a 4-(azetidin-1-yl)piperidine in compound 24. 
 





































a). Calcium mobilization FLIPR assays, IP values represent the numerical average of at least two experiments. b). 
The maximal efficacy normalized to the maximal efficacy of human ACh ranged from 80 to 102%. c). Competition 
binding Ki using [3H]1, values represent the numerical average of at least two experiments. d). n = 1, single number 
in italics; n = 2, geometric mean reported, the italicized values in parentheses represent the two measurements; n > 
2, geometric mean reported, the values in parentheses represent the lower and upper limits of the 95% confidence 
intervals.   
 
  
With multiple compounds demonstrating significantly improved binding affinity (Tables 
2-4) over compound 1, the next step was to examine the physiochemical properties of these 
analogs and assess their likelihood of improved in vivo profiles.  Analogs with sub-nanomolar 
binding affinity were selected (compounds 9, 13, 20, 22, 23, 24 and 25).  In addition, we also 
selected compound 2 as an example with moderately improved Ki compared with compound 1, 
which served as the baseline comparison.  Table 5 summarizes the in vitro profiles of these 
analogs, including their Ki, P-gp efflux ratio, and apparent permeability (Papp).  We have also 
included free fractions in plasma and in brain, as these parameters have been identified as useful 
 
surrogate measures of non-specific brain binding, critical to the in vivo performance of a PET 
tracer.30  Free fraction values in plasma from rhesus monkey were reported when available, and 
they generally correlated with in vitro measures of lipophilicity for the series.  Brain free fraction 
values using rat brain homogenate were not routinely measured in our laboratories, but were 
determined for a few key compounds. The lipophilicity of the compounds was first estimated by 
HPLC Log D, which was a high throughput determination of Log D (see experimental section 
for detail).  Compounds of interest were further characterized by shake-flask Log D (sF log D).  
In most cases, HPLC Log D values correlated well with their sF Log D’s.  Compounds 9 and 23 
have HPLC Log D values of 3.6 and 3.8 respectively, exceeding the desired cut-off value of 3.5 
and indicating an increased potential for non-specific binding.  Compound 20 was within the 
desired lipophilicity range (HPLC LogD = 2.4).  However, with the introduction of the ketone 
functionality, the compound also acquired liability as human P-gp substrate.  Similarly, 
compounds 24 and 25 were also P-gp substrates, and we decided to exclude these P-gp substrates 
as tracer candidates. 
Table 5: Physicochemical properties of tracer candidates 
Compound structure 




















3.1 2.2 2.5 1.2 29.5 7.2 16.6 
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0.6 3.6 ND ND ND ND ND 
13 
 
0.19 2.9 2.7 0.7 28.8 17 4.3 
20 
 
0.16 2.4 ND 9.4 25 ND ND 
22 
 
0.20 3.0 2.7 0.6 29 5.1 3.3 
23 
 
0.12 3.8 ND 0.8 23 ND ND 
24 
 
0.24 3.3 ND 34 19 ND ND 
25 
 
0.62 2.4 ND 8.4 26 ND ND 
a) Ki values from Tables 2–4. b) P-gp efflux ratio measured at 1 M in LLC-PK1 cell line expressing human (human 
LLC-MDR1) P-gp. A ratio of >2.5 indicates substrate liability. c) single determination. ND: not determined. 
 
 Compounds 2, 13 and 22 showed overall acceptable physicochemical properties to merit 
further study.  Compounds 2 and 13 were radiolabeled with [11C]iodomethane ([11C]CH3I) in the 
last step of the synthesis, while 22 was labeled with [11C]HCN.   Baseline PET scans for [11C]2, 
 
[11C]13 and [11C]22 in rhesus monkeys revealed non-displaceable binding potential (BPND) in 
striatum (Table 6).  Although tracer [11C]2 did provide a measurable BPND (0.29), it was deemed  
too low for accurate quantification of the receptor occupancy of a therapeutic drug (Figure 4).  
The overall improved in vitro profile of compound 13 translated into an improved BPND of 0.83 
in vivo.  In contrast, despite sub-nanomolar binding affinity for compound 22, it failed to further 
improve BPND in vivo (for compound [
11C]22, BPND = 0.2); time-activity curves and baseline 
PET images were very similar to [11C]2.  As previously described, non-specific tissue binding is 
important for the utility of a potential PET tracer in vivo.   Compound 13 and 22 showed similar 
lipophilicity when measured by water–octanol partitioning, but behaved differently in biological 
matrices.  The free fraction in rhesus plasma of compound 22 was approximately 3-fold lower 
compared to compound 13.  The free fraction in homogenized rat brain tissue also trended lower 
for compound 22, suggesting higher non-specific binding in vivo (Table 5).  
 
 
Figure 4. A: Time-activity curves in rhesus monkey striatum (blue) and cerebellum (green) for 
[11C]2 at baseline conductions. B: [11C]2 baseline PET image (0–90 minutes). Highest tracer 




















Table 6. Measured in vivo BPND in rhesus monkey striatum for tracers [
11C]2, [11C]13 and [11C]22 
       
Compound Striatum BPND 
[11C]2 0.29 ± 0.06 (4 scans in two monkeys) 
[11C]13 0.83 ± 0.17 (10 scans in five monkeys)  
[11C]22 0.1/0.2 (2 scans in one monkey) 
 
With encouraging in vivo data obtained for compound 13, we sought to further refine the 
structure of 13 to improve the binding potential BPND.  We made additional modifications on R5 
and substitution X on the pyrazole.  The data are summarized in Table 7.  The binding affinity 
for compound 26 was similar to compound 13 (R5 = Me, Ki = 0.26 nM).  The lipophilicity for 
this compound measured by sFlogD was within the desirable range (3.1).  It is also highly 
permeable and has no P-gp liabilities.  However, when radiolabeled with [11C]CH3I and 
evaluated in a PET imaging study, [11C]26 failed to improve binding potential over [11C]13 
(BPND = 0.37 for compound 26, Table 7).  Chloro-substitution at R5 in compound 27 showed 
similar binding affinity as compound 26.  However, the addition of the chlorine atom increased 
HPLC Log D to 3.6, indicating potential for higher non-specific binding.  Substitution on the 
pyrazole ring (labeled as X) was also studied.  A fluorine at this position improved binding 
affinity when compared with the unsubstituted compound 13 (compound 28, Ki = 0.08 nM, 
 
Table 7).  The physiochemical properties of compound 28 also met all the criteria for a potential 
PET tracer.   However, larger halides or pseudohalides at X showed detrimental effect on 
binding affinity, as Ki for both compounds 29 and 30 were > 1 nM.  From this group of 
compounds, compound 28 was radiolabeled with [11C]CH3I, and the BPND in monkey was 
determined to be 0.42 (Table 7), still lower than compound 13.  This result could be attributed to 
the higher non-specific binding of compound 28 observed during tracer studies, in line with the 
higher sF Log D value and higher brain tissue binding (Table 7). 
Table 7. Further optimization of compound 13 scaffold. 
                                
 







































3.4 ND ND ND ND ND ND 
 
a) Competition binding Ki using [3H]1, values represent the geometric average of at least two experiments. b) n = 1, 
single number in italics; n = 2, geometric mean reported, the italicized values in parentheses represent the two 
measurements; n > 2, geometric mean reported, the values in parentheses represent the lower and upper limits of the 
95% confidence intervals. c) P-gp efflux measured at 1 M in LLC-PK1 cell line expressing human (human LLC-
MDR1) P-gp. A ratio of >2.5 indicates substrate liability; ND: not determined. d) single determination. 
 
Since no further improvement of in vivo binding potential was achieved, efforts were 
focused on the in-depth characterization of 13 as a potential M4 PAM PET tracer clinical 
candidate.  The molecular pharmacology profile of 13 as an M4 PAM was studied.  Compound 
13 was shown to be a PAM of ACh function in a cell-based Ca++ mobilization assay.  In this 
assay, increasing concentrations of 13 potentiated the ability of a fixed concentration of ACh 
(EC20) to mobilize intracellular Ca
++, with compound 13 exhibiting an EC50 of 27 nM.  Further 
characterization of the allosteric nature of compound 13 was carried out by conducting a matrix 
of dose-response curves of ACh at 15 concentrations of 13.  A global curve fitting method was 
used to analyze the resulting curves according to a modified ternary complex model.31, 32 The 
shift parameters for compound 13 are summarized in Table 8, and shift curves are shown in 
Figure 5 .  
Table 8. FLIPR shift parameters for compound 13a 
species α Kb τβ 
human 43 (32–78) 14 (6–22) 1.5 (1.2–1.6) 
rhesus 
monkey 
34 (32–36) 0.64 (0.55–0.74) 0.79 (0.71–0.88) 
a) Binding Affinity (Kb), Cooperativity (α), and Intrinsic Efficacy (τβ) estimates of test compounds 
on mAChR in the calcium mobilization assay in the presence of ACh for the human rhesus monkey 
receptors. b) All parameters reported as geometric means with the range of individual runs reported 





Figure 5. Compound 13 potentiation of ACh induced Ca++ mobilization in CHO-hM4-Gqi5 
cells.  Increasing concentrations of ACh were assayed for increases in Ca++ mobilization in the 
presence of 0-22 µM compound 13, resulting in a leftward shift of the ACh dose response curve. 
 
 [11C]13 was further evaluated in five rhesus monkeys to assess brain uptake and specific 
binding to the M4 allosteric site.  Baseline PET scans in five monkeys after a single intravenous 
administration revealed that [11C]13 rapidly penetrated the blood/brain barrier and distributed as 
expected based on the known presence of M4 receptors in the brain. The highest tracer uptake 
was noted in the striatum region, consistent with autoradiography results of [3H]1. A blockade 
experiment (Figure 7) was also carried out with compound 31 (Figure 6),28 a potent M4 PAM. 
Injection of [11C]13 (189 MBq, 1.4 g mass of 13), following intravenous administration of 3 
mg/kg compound 31, resulted in significant reduction (receptor occupancy = 87%) in tracer 
 
uptake in the striatum relative to the baseline PET scan with [11C]13. This result indicated the 
ability of [11C]13 to determine an M4 PAM plasma/receptor occupancy relationship with a 
robust specific signal for structurally similar M4 PAM molecules.   
An off-target screening of compound 13 was performed against a neuro panel of 115 
receptors and enzymes by Eurofins Panlabs (Taipei, Taiwan). Compound 13 showed >3,600-fold 
selectivity against the majority of those targets, including other mAChRs in these binding assays. 
Compound 13 displayed only weak binding (IC50 > 1µM) to adenosine transporter. As PET 
tracers should have high affinity to show robust specific binding signal and are only administered 
as microdoses, off-target binding at the measured weak potencies is not expected to be a concern 
for the safety or imaging characteristics of [11C]13.  Additional off-target profiling of 13 in a high 
throughput ion channel flux assays revealed IC50 > 30 µM against Nav 1.5, Cav 1.2 and Ikr ion 
channels. 
 




Figure 7. (A) Co-registered transverse PET/MRI summed image (0-90 min) of [11C]13 in rhesus 
monkey highlighting tracer uptake in the striatum. The left image [11C]13 baseline, and the right 
image includes blockade with compound 31. The scale is shown in Standardized Uptake Value 
(SUV) units, which are normalized for the injected dose and mass of the monkey. (B) [11C]13 
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In summary, a high quality M4 PAM PET tracer [11C]13 (MK-6884) was developed 
through optimization of binding affinity and balancing physicochemical properties of the initial 
lead compound. This PET tracer exhibited good brain uptake and M4-specific signal in rhesus 
monkey PET studies, and was used to determine plasma concentration/ receptor occupancy for 
M4 PAM therapeutic candidates in monkeys.  Detailed information regarding plasma 
concentration vs M4 receptor occupancy relationship in monkey brain, as well as the clinical  
investigations of  [11C]13, will be the subject of future publications. 
CHEMISTRY 
Scheme 1. General synthetic approach to analogs. 
 
Reagents and conditions: (a) Pd(dppf)Cl2, K2CO3, dioxane/H2O, 30-60
oC, 3h; (b) Pd(dppf)Cl2, 
K2CO3, dioxane/H2O, 60
oC, 10 h, or NaOtBu , RuPhos Pd pre-catalyst, THF, rt, 1h. 
 
Compounds were accessed through the generic synthetic routes outlined in references 28 
and 29. A general approach is illustrated in Scheme 1.  An appropriately substituted pyridine 
starting material 32a was coupled with previously prepared pyrazole analog 3228, 29 under 
standard Suzuki coupling conditions to afford intermediate 33.  The chlorine handle in 
intermediate 33 then undergoes either Suzuki coupling or C-N coupling to afford final targets.  
Synthesis of compounds 13 and 22 is described in Scheme 2. The synthesis begins with a 
palladium mediated coupling under standard conditions with commercially available 5-bromo-6-
 
chloropicolinonitrile (34) and pinacol borate 35 to provide intermediate 36 in high yield.  With 
36 in hand, 13 is produced under palladium mediated cross-coupling with pinacol borate 37 in 
good yield. The [11C] and [3H] labelled compound 13 was obtained using compound 40 as 
precursor. Compound 40 was synthesized using a similar method of Suzuki cross-coupling of 
compound 36 with boronic ester 39 to afford the des-methyl lactam compound 40 as the labeling 
precursor for compound 13. A C-N coupling with 36 and 38 catalyzed by RuPhos Pd pre-catalyst 
afforded compound 22. Analogs of 13-17, 21-25 were obtained using the same approach.   
Scheme 2. Synthesis of compound 13, 22 and 40. 
 
Reagents and conditions: (a) Pd(dppf)Cl2, K3PO4, THF/H2O, 50
oC, 1h, 91%; (b) Pd(dppf)Cl2, 
K3PO4, dioxane/H2O, 60
oC, 5 h, 66%; (c) NaOtBu, RuPhos Pd pre-catalyst, THF, rt, 1h, 88%, d) 
Pd(dtbpf)Cl2, K3PO3, TFH/H2O, 60
oC, 2h, 45%; 
 
The synthesis of compounds 18 and 26 started with commercially available material 41 (Scheme 
3). Selective palladium mediated Suzuki coupling with compound 35 gave intermediate 42. 
 
Another selective Suzuki coupling compound 37 afforded compound 43. The chlorine of 
compound 43 was further converted to nitrile or methyl using palladium chemistry to yield 
compounds 18 and 26, respectively.  
Scheme 3. Synthesis of compound 18 and 26. 
 
Reagents and conditions: (a) Pd(dppf)Cl2, K2CO3, dioxane/H2O, 60
oC, 10 h, 66%; (b) 
Pd(dppf)Cl2, K2CO3, dioxane/H2O, 85
oC, 10 h, 96%; (c) trimethylboroxine, Pd(dtbpf)Cl2, 
K2CO3, dioxane/H2O, 100
oC, 2 h, 51%; (d) ZnCN2, bis(tri-tert-butylphosphine)palladium(0), 
microwave, 180oC, 15 min., 88%. 
 
 Substituted pyrazole analogs 28-30 were synthesized by halogenation of intermediate 36 
to afford chlorinated and fluorinated intermediates 44 and 45 respectively (Scheme 4).  Further 
Suzuki coupling affords compounds 28 and 29.  Chloropyrazole analog 29 can be further 
converted to the nitrile-containing compound 30 using palladium mediated coupling with 
ZnCN2. 
Scheme 4. Synthesis of compounds 28-30 
 
 
Reagents and conditions: (a) SELECTFLUOR, acetonitrile, microwave, 180oC, 30 min., 14%; 
(b)  Pd(dppf)Cl2, K2CO3, dioxane/H2O, microwave, 110
oC, 1 h, 72%; (c) NCS, acetonitrile, 
microwave, 100oC, 30 min., 67%; (d) Pd(dppf)Cl2, K2CO3, dioxane/H2O, microwave, 115
oC, 1 
h, 80%; (e) ZnCN2, Xphos Pd G2, DMF, microwave, 200
oC, 30 min., 42%. 
 
EXPERIMENTAL SECTION       
Biological Evaluation   
In Vitro Function Assay  FLIPR assays were used to assess human M4 activity and were 
performed as previously reported.29 CHO-K1 cells stably transfected with human M4 receptor 
and chimeric G-protein Gαqi5 are thawed from liquid N2 storage, resuspended in growth 
medium, plated in black, clear bottom 384 well plates, and incubated 16-20 hours at 37 °C, 5% 
CO2. On the day of assay, growth medium is removed, the cells are washed 2 times with wash 
buffer, and cells are incubated in dye loading buffer at 37 °C, 5% CO2 for ~1 hour.  Following 
dye loading the cell plates are placed in a FLIPR Tetra instrument and while monitoring dye 
fluorescence (excitation 470-495 nM/emission 515-575 nM), 10 L of test substance at 
increasing concentrations is added, and fluorescence values are recorded for 4 min.  Next, 10 L 
of acetylcholine is added (final concentration calculated so as to achieve 20% of the maximum 
 
acetylcholine response), and the fluorescence reading is continued for 3.5 min.  In some cases, a 
third addition of acetylcholine (final concentration calculated to achieve 70% of the maximal 
acetylcholine response) is performed. Unless otherwise noted, a minimum of two independent 
experiments (N ≥ 2) were performed for each compound. 
FLIPR™ ACh Shift Assay 
CHO-K1 cells stably transfected with human M4 receptor and chimeric G-protein Gαqi5 stably 
expressing a specific human, rat or rhesus muscarinic receptor subtype, were taken from LN2 
storage, thawed rapidly at 37° C, washed with CHO basal medium and dispensed in 384 well 
black, clear bottom plates at ~20,000 cells per well.  After incubation overnight at 37° C, 5% 
CO2, 95% relative humidity, the medium was removed and replaced with 25 µl per well of 
Calcium 5 dye buffer (Fluo-5 reagent in HBSS, 20 mM HEPES, 2.5 mM probenecid), followed 
by incubation at 37° C for 52 min., and subsequently 8 min. at room temperature.  The plates 
were then loaded into the FLIPR™ instrument where 25 µl of 0.1% DMSO was added to the 
cells while detecting fluorescence (excitation 470-495 nm/emission 515-575 nm) for 5 min., 
followed by addition of 25 µl of test compound plus ACh, and continued detection of 
fluorescence for 5 min.  For further data analysis, a max-min value was determined for each well 
by subtracting the minimum fluorescence signal observed immediately prior to compound 
addition from the maximum fluorescence signal observed in the time following compound 
addition. 
The compounds for assay (ACh and test article) were prepared by serial, 3.16 fold dilution of 10 
mM DMSO stock solutions into neat DMSO.  Fifty nanoliters of the diluted ACh and 500 nL of 
diluted test compounds are then added to 75 µl assay buffer (HBSS, 20 mM HEPES, pH 7.4) in a 
 
matrix fashion such that each concentration of test compound was assayed with a complete dose 
range of ACh.  
Competition Cell Binding Assay 
Competition binding of M4 allosteric analogs (in the presence of 10 µM ACh at hM4 receptors 
expressed in CHO cells were assessed with a tritium-labeled version, [3H]1. Cell membranes 
from human M4 expressing CHO cells (CHO-hM4), suspended in assay buffer (20 mM HEPES, 
100 mM NaCl, 5 mM MgCl2, pH 7.4) at 50 µg/ml, were combined with test article at increasing 
concentrations, ACh (10 M final concentration) and radioligand [3H]1 (2.2 nM final 
concentration) and allowed to incubate for 1.5 hour at room temperature with gentle shaking.  
Additional samples were also prepared to define total binding, containing DMSO (0.5% final 
concentration), or non-specific binding, containing compound 31 (10 µM). Following this 
incubation, the samples were filtered through GF/C filter plates (that had been pre-treated with 
0.3% PEI for 30 minutes) and washed 5 times with cold wash buffer (20 mM HEPES,154 mM 
NaCl, pH 7.4).  The filter plates were dried under vacuum for 30-60 min. at 40° C.  Fifty 
microliters of Microscint 20 were added to each well, and the plates were read on a Topcount. 




Autoradiography with [3H]1 in mouse brain slices was performed similar to previously reported 
methods.33 Brain slices were incubated with [3H]1 (5.0 nM) at room temperature for 60 minutes 
(binding buffer with or without 10 μM carbachol). Nondisplaceable binding was defined with 
unlabeled 1 (2 µM). Washed and dried slides (3’ x 3) were placed into a cassette against a Fuji 
 
Imaging plate (TR2025) for 1 week at room temperature. The plate was scanned in Fujifile Life 
Science BAS-5000. Images were analyzed using MCID software. 
 
In Vitro Tissue Binding Studies 
 
In vitro tissue binding studies with [3H]1 in rhesus monkey and human brain striatum 
homogenates were performed analogs to previously reported procedures.33 Assay buffer 
contained 50mM Tris HCl pH 7.5, 100mM NaCl, 5mM MgCl2, 2% DMSO, 10μM carbachol and 
1:1000 mammalian protease inhibitors (P8340). Wash buffer was the same as the assay buffer 
without 2% DMSO and 10μM carbachol. Nondisplaceable binding was determined with 
unlabeled 1 (2 µM). The results were analyzed by nonlinear regression of curve fit using Prism 
software. The Bmax values (in nM) of [
3H]1 calculated from assay tubes were converted to the 
Bmax values using the wet tissue weight by multiplying the tissue dilution factor in the assay. 
 
HPLC LogD 
The high throughput (HT) HPLC Log D (pH 7) value is determined by the following method. 
The chromatographic system consists of an Agilent 1100 HPLC/DAD system and ChemStation 
software, both from Agilent Technologies, USA. The separations are carried out on a Poroshell 
120 EC-C18 column, 30 mm x 3.0 mm I.D., 2.7 µm (Agilent Technologies, USA). The mobile 
phase consists of Potassium phosphate saline (10 mM Potassium phosphate, 150 mM Sodium 
chloride) buffered at pH 7 (mobile phase A) and acetonitrile (mobile phase B).  The column oven 
temperature is set to 30C and the HPLC analysis consists of a gradient.  The injection volume is 
5 µL and the spectrophotometric detection is set to 215, 238, and 254 nm. The chromatographic 
system is calibrated with a set of standards with published shake-flask Log D (pH 7) values.  
Linear regression is used to determine the calibration line relating the retention time to Log D for 
 
the calibration standards.  This best-fit line is then used to determine the HT HPLC Log D (pH 7) 
value of API (active pharmaceutical ingredient) from its measured retention time by the 




General procedures.  Reactions were conducted, purified, and analyzed according to methods 
widely practiced in the field, while taking necessary precautions in the exclusion of moisture 
and/or oxygen where appropriate.  Final compounds were tested in biological assays as either 
TFA salts, HCl salts, or free bases.  Although where relevant, the exact salt content was not 
determined, its mole equivalent was assumed to be equal to the number of basic moieties 
residing in the molecule for purposes of yield and Ki calculations.  LC/MS analyses were 
performed on Agilent 1200 Series HPLC equipped with  DAD & 6110 single quadrupole MSD 
& ELSD with Agilent TC-C18, 50×2.1mm, 5μm for acid methods, Waters X-Bridge 
ShieldRP18, 50*2.1mm 5μm for basic methods.  All tested compounds exhibited ≥ 95% purity 
under the LC conditions except for compounds 7, 10, 11, 25, 29 and 30.  UHPLC/HRMS 
analysis of compound 13 was performed using the following condition: LC/MS analysis was 
performed on a Waters Acquity UPLC system, consisting of a binary pump, a sample manager, a 
TUV detector and a Waters Synapt G1 Mass Spectrometer (Waters, Milford, MA) under positive 
or negative ESI conditions. The output signal was monitored and processed using MassLynx 
software designed by Waters (Milford, MA).  NMR spectra were recorded on a Varian 400 MHz, 
500 MHz  or Bruker 400 MHz spectrometers.  Residual proteo-solvent was used as internal 
standard for chemical shift assignments.  Coupling constants are provided in Hz, with the 
 
following spectral pattern designations: s, singlet; d, doublet; t, triplet; q, quartet; br, broad; m, 
multiplet, o, overlapped. IUPAC nomenclature was adopted for all final compounds and key 
intermediates.  Compounds 1–12, 14, 16, 19, and 20 were synthesized according to previously 
published procedures which follows the same approach described in Scheme 2 and conditions 
described Schemes 3 and 4.28, 29 
 
5-{1-[(1-Methylcyclopentyl)methyl]-1H-pyrazol-4-yl}-6-(2-methyl-3-oxo-2,3-dihydro-1H-
isoindol-5-yl)pyridine-2-carbonitrile (13).  
Into a 250 mL round bottom flask, purged and maintained with an inert atmosphere of nitrogen, 
was placed compound 35 (1.39 g, 4.8 mmol), 5-bromo-6-chloropyridine-2-carbonitrile 34 (0.87 
g, 4.0 mmol), Pd(dppf)Cl2 (156 mg, 0.24 mmol), potassium phosphate ( 6 mL, 2.0 N aqueous 
solution) and THF (25 mL). The resulting solution was stirred for 1 h at 50 °C. The reaction was 
then quenched by the addition of water (2 L) and was partitioned with EtOAc (3 L x 3). The 
combined organic layers were dried over anhydrous sodium sulfate and concentrated under 
reduced pressure. The residue was applied onto a silica gel column (5:1 petroleum ether:EtOAc) 
to yield compound 36 (1.1 g, 91%). 1H NMR (400 MHz, CDCl3):  8.00 (s, 1H), 7.92–7.94 (m, 
1H), 7.86 (s, 1H), 7.64 (s, 1H), 4.09 (s, 2H), 1.42–1.74 (m, 6H), 1.38–1.42 (m, 2H), 1.01 (s, 3H). 
LC/MS m/z: [M+H]+ calcd for C16H17ClN4, 301.12; found 301.1.  
To a mixture of compound 36 (1.2 g, 3.99 mmol),  compound 37 (1.1 g, 4.39 mmol),  potassium 
phosphate(2.13 g, 7.98 mmol) was added H2O (4 mL) and dioxane (16 mL) under an atmosphere 
of N2. 1,1'-Bis(di-tert-butylphosphino)ferrocene palladium dichloride (584 mg, 0.80 mmol) was 
added and the system was a purged and flushed with N2 and it was stirred at 60 °C for 5 hr.  
After cooling to RT, the reaction was diluted with water and was extracted with EtOAc. The 
 
organic was dried with anhydrous sodium sulfate and was concentrated under reduced pressure. 
The crude material was purified by silica gel column (0-60% 3:1 EtOAc:EtOH/hexanes) to yield 
the title compound 13 (1.1 g, 66%). 1H NMR (500 MHz, DMSO-d6): δ 8.21 (d, J = 5.0 Hz, 1H), 
8.05 (d, J = 5.0 Hz, 1H), 7.65–7.60 (m, 3H), 7.38 (s, 1H), 7.32 (s, 1H), 4.52 (s, 2H), 3.86 (s, 2H), 
3.09 (s, 3H), 1.46–1.58 (m, 4H), 1.36–1.40 (m, 2H), 1.10–1.14 (m, 2H), 0.75 (s, 3H). 13C NMR 
(126 MHz, DMSO-d6): δ 167.7, 157.6, 142.5, 139.4, 138.4, 138.4, 133.2, 132.4, 132.1, 131.3, 
129.9, 128.4, 123.9, 123.5, 118.1, 117.7, 60.9, 51.9, 44.1, 37.1, 29.5, 24.9, 24.2.   
HRMS m/z: [M+H]+ calcd for C25H26N5O, 412.2137; found 412.2146. 
 
6-(6-Fluoro-3-{1-[(1-methylcyclopentyl)methyl]-1H-pyrazol-4-yl}pyridin-2-yl)-2-methyl-
2,3-dihydro-1H-isoindol-1-one (14). Compound 14 was synthesized using the same approach 
described in Scheme 2. 1H NMR (500 MHz, DMSO-d6) δ 8.09 (t, J = 8.2 Hz, 1H), 7.58 (s, 3H), 
7.31 (s, 1H), 7.29 (s, 1H), 7.25 (dd, J = 8.4, 3.2 Hz, 1H), 4.49 (s, 2H), 3.86 (s, 2H), 3.08 (s, 3H), 
1.46–1.60  (m, 4H), 1.39 (d, J = 6.0 Hz, 2H), 1.09–1.19 (m, 2H), 0.76 (s, 3H). LC/MS m/z: 
[M+H]+ calcd for C24H25FN4O, 405.2; found 405.4.  
 
6-(5-Fluoro-3-{1-[(1-methylcyclopentyl)methyl]-1H-pyrazol-4-yl}pyridin-2-yl)-2-methyl-
2,3-dihydro-1H-isoindol-1-one (15). Compound 15 was synthesized using the same approach 
described in Scheme 2. 1H NMR (500 MHz, CDCl3) δ 8.43 (d, J = 2.1 Hz, 1H), 7.88 (s, 1H), 
7.54 (d, J = 7.8 Hz, 1H), 7.51 (dd, J = 9.1, 2.7 Hz, 1H), 7.42 (d, J = 7.8 Hz, 1H), 7.29 (s, 1H), 
6.89 (s, 1H), 4.40 (s, 2H), 3.85 (s, 2H), 3.20 (s, 3H), 1.51–1.71  (m, 4H), 1.42 (dt, J = 12.8, 6.5 
Hz, 2H), 1.17–1.31 (m, 2H), 0.82 (s, 3H). LC/MS m/z: [M+H]+ calcd for C24H25FN4O, 405.2; 




isoindol-5-yl)pyridine-4-carbonitrile (16). Compound 16 was synthesized using the same 
approach described in Scheme 2. 1H NMR (500 MHz, DMSO-d6) δ 8.82 (d, J = 5.0 Hz, 1H), 
7.95 (d, J = 5.0 Hz, 1H), 7.49–7.64  (m, 4H), 7.37 (s, 1H), 4.45 (s, 2H), 3.93 (s, 2H), 3.06 (s, 
3H), 1.46–1.63  (m, 4H), 1.39 (d, J = 5.8 Hz, 2H), 1.07–1.21  (m, 2H), 0.74 (s, 3H). LC/MS m/z: 
[M+H]+ calcd for C25H25N5O, 412.2; found 412.4.  
 
6-(6-Fluoro-5-methyl-3-{1-[(1-methylcyclopentyl)methyl]-1H-pyrazol-4-yl}pyridin-2-yl)-2-
methyl-2,3-dihydro-1H-isoindol-1-one (17). Compound 17 was synthesized using the same 
approach described in Scheme 2.  1H NMR (400 MHz, MeOD) δ 7.90 (d, J = 9.2 Hz, 1H), 7.70 (s, 
1H), 7.54–7.64 (m, 2H), 7.33 (s, 1H), 7.16 (s, 1H), 4.52 (s, 2H), 3.89 (s, 2H), 3.19 (s, 3H), 2.37 (s, 
3H), 1.58–1.60 (m, 2H), 1.38–1.50 (m, 2H), 1.25–1.31 (m, 2H), 1.13–1.22 (m, 2H), 0.79 (s, 3H). 





Compound 35 (288 mg, 0.993 mmol), 2-bromo-6-chloro-3-iodo-5-methylpyridine (41) (300 mg, 
0.903 mmol), 1,1'-bis(diphenylphosphino)ferrocene-palladium(ii)dichloride dichloromethane 
complex (73.7 mg, 0.090 mmol) and potassium carbonate (2.71 ml, 2.71 mmol) were charged in 
a reaction vessel with Dioxane (5 ml).  The mixture was de-gassed three times before it was 
 
heated to 60°C for 10 hr. The reaction mixture was worked up and concentrated to dryness and 
purified with ISCO eluted with EtOAc in Hex 0% to 40% to afford compound 42 (220 mg, 
66%). 
Compound 42 (120 mg, 0.325 mmol), compound 37 (89 mg, 0.325 mmol), 1,1'-
bis(diphenylphosphino)ferrocene-palladium(ii)dichloride dichloromethane complex (26.6 mg, 
0.033 mmol) and potassium carbonate (0.976 ml, 0.976 mmol) were charged in a reaction vessel 
with dioxane (5 ml).  The mixture was de-gassed three times before it was heated to  85 °C for 
10 hr.  LCMS showed mostly product.  The reaction mixture was worked up and concentrated to 
dryness and purified with ISCO column (24 g) eluted with EtOA in Hex 50% to 100% to give 
compound 43 (136 mg, 96 %). 
2,4,6-Trimethyl-1,3,5,2,4,6-trioxatriborinane (6.93 mg, 0.055 mmol), compound 43 (20 mg, 
0.046 mmol) and 1,1'-bis(di-tert-butylphosphino)ferrocene palladium dichloride (3.00 mg, 4.60 
µmol) were placed in a 4 mL reaction vial and evacuated and charged with nitrogen. 1,4-Dioxane 
(1 mL) and potassium (3 M in water, 0.138 mL, 0.138 mmol) were added to the sealed vial and 
the system was heated to 100 °C.  After 2 h, the crude reaction mixture was cooled and purified 
by mass triggered reverse phase HPLC (ACN/water with 0.1% NH4OH modifier) to afford 
compound 18 (9.8 mg, 51%). 1H NMR (500 MHz, CDCl3):  7.9 (s, 1H), 7.6 (d, J = 8.6 Hz, 1H), 
7.57 (s, 1H), 7.4 (d, J = 7.8 Hz, 1H), 7.3 (s, 1H), 6.86 (s, 1H), 4.4 (s, 2H), 3.86 (s, 2H), 3.23 (s, 
2H), 2.6 (s, 2H), 2.4 (s, 2H), 1.60–1.73 (m, 4H), 1.40–1.50 (m, 2H), 1.20–1.30 (m, 2H), 0.85 (s, 
2H). LC/MS m/z: [M+H]+ calcd for C26H30N4O, 415.3; found 415.3.  
 
6-[5-Fluoro-6-(fluoromethyl)-3-{1-[(1-methylcyclopentyl)methyl]-1H-pyrazol-4-yl}pyridin-
2-yl]-2-methyl-2,3-dihydro-1H-isoindol-1-one (19). Compound 19 was synthesized using the 
 
same approach described in Scheme 2.  1H NMR (500 MHz, CDCl3) δ 7.91 (s, 1H), 7.52–7.61  
(m, 2H), 7.42 (d, J = 7.7 Hz, 1H), 7.30 (s, 1H), 6.89 (s, 1H), 5.57 (d, J = 47.5 Hz, 2H), 4.40 (s, 
2H), 3.85 (s, 2H), 3.21 (s, 3H), 1.51–1.71 (m, 4H), 1.42 (dt, J = 12.5, 6.3 Hz, 2H), 1.25 (d, J = 
7.5 Hz, 2H), 0.82 (s, 3H). LC/MS m/z: [M+H]+ calcd for C25H26F2N4O, 437.2; found 437.0.  
 
3-{1-[(1-Methylcyclopentyl)methyl]-1H-pyrazol-4-yl}-2-(2-methyl-3-oxo-2,3-dihydro-1H-
isoindol-5-yl)-5,6-dihydro-7H-cyclopenta[b]pyridin-7-one (20). Compound 20 was 
synthesized using the same approach describe in Scheme 2.  1H NMR (400MHz, MeOD) δ 8.18 
(s, 1H) 7.61–7.70 (m, 3H), 7.43 (s, 1H), 7.12 (s, 1H), 4.53 (s, 2H), 3.86 (s, 2H), 3.22–3.27 (m, 
2H), 3.18 (s, 3H), 2.76–2.83 (m, 2H), 1.66–1.77 (m, 2H), 1.58 (d, J = 8.2 Hz, 2H), 1.43 (dd, J = 
14.9, 7.4 Hz, 2H), 1.11–1.20 (m, 2H), 0.76 (s, 3H). LC/MS m/z: [M+H]+ calcd for C27H28N4O2, 
441.2; found 441.2.  
 
6-(Imidazo[1,2-a]pyridin-7-yl)-5-{1-[(1-methylcyclopentyl)methyl]-1H-pyrazol-4-
yl}pyridine-2-carbonitrile (21). Compound 21 was synthesized using the same approach 
described in Scheme 2.  1H NMR (400MHz, MeOD) δ 8.80 (d, J = 6.8 Hz, 1H), 8.28 (s, 1H), 
8.21 (d, J = 8.4 Hz, 1H), 8.11(s, 1H), 8.09 (s, 1H), 8.00 (d, J = 8.0 Hz, 1H), 7.61 (s, 1H), 7.54 (s, 
1H), 7.48 (d, J = 6.8 Hz, 1H),  3.96 (s, 2H), 1.45–1.70 (m, 6H), 1.20–1.30 (m, 2H), 0.84 (s, 3H). 
LC/MS m/z: [M+H]+ calcd for C23H22N6, 383.2; found 383.2 
 
6-(5,6-Dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-5-{1-[(1-methylcyclopentyl)methyl]-1H-
pyrazol-4-yl}pyridine-2-carbonitrile (22).  
 
To a suspension of compound 36 (20 mg, 0.066 mmol), compound 38 (12 mg, 0.1 mmol) in THF 
(332 L) under N2 was added RuPhos Pd pre-catalyst (4.85 mg, 6.7 mol) and sodium tert-
butoxide (133 L, 2.0 N THF solution, 0.27 mmol).  The mixture was stirred at room 
temperature for 1 h.  The reaction was diluted with EtOAc (3 mL).  The organic layer was 
removed and the aqueous layer was further extracted with EtOAc (2x3 mL). The combined 
organic layer was washed with brine, and dried using anhydrous Na2SO4.  QuardraPure was 
added and stirred at rt for 1 hr to remove Pd.  The solution was then filtered and concentrated to 
dryness under reduced pressure. The crude material was purified by Gilson reverse phase HPLC 
using Sunfire C18 (19x150 mm column), mobile phase A, 0.1% TFA in H2O, mobile phase B, 
0.1% TFA in acetonitrile, gradient, 15-75% B, 20 mins run. Compound 22 (28 mg, 88%). 1H 
NMR (500 MHz, DMSO-d6) δ 8.36 (s, 1H), 8.04–8.11 (m, 2H), 7.76 (d, J = 7.8 Hz, 1H), 7.67 (s, 
2H), 4.67 (s, 2H), 4.11 (d, J = 5.1 Hz, 2H), 4.06 (s, 2H), 3.64 (d, J = 5.0 Hz, 2H), 1.61 (s, 6H), 
1.28 (s, 2H), 0.92 (s, 3H). LC/MS m/z: [M+H]+ calcd for C22H25N7, 388.2; found 388.3. 
 
6-(2-Bromo-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-5-{1-[(1-
methylcyclopentyl)methyl]-1H-pyrazol-4-yl}pyridine-2-carbonitrile (23). Compound 23 was 
synthesized using the same approach described in Scheme 2. 1H NMR (500 MHz, DMSO-d6) δ 
8.26 (s, 1H), 7.93–8.03 (m, 2H), 7.69 (d, J = 7.7 Hz, 1H), 7.28 (s, 1H), 4.26 (s, 2H), 4.04 (s, 2H), 
~3.4–4.0 (m, 2H), 1.59 (s, 6H), 1.25 (s, 2H), 0.90 (s, 3H). LC/MS m/z: [M+H]+ calcd for 
C22H24BrN7, 466.1; found 468.3. 
 
6-[4-(3-Methylazetidin-1-yl)piperidin-1-yl]-5-{1-[(1-methylcyclopentyl)methyl]-1H-pyrazol-
4-yl}pyridine-2-carbonitrile (24). Compound 24 was synthesized using the same approach 
 
described in Scheme 2. 1H NMR (500 MHz, DMSO-d6) δ 8.24 (s, 1H), 7.99 (s, 1H), 7.94 (d, J = 
7.7 Hz, 1H), 7.63 (d, J = 7.7 Hz, 1H), 4.00–4.31 (m, 4H), 3.61–3.85 (m, 2H), 3.47–3.59 (m, 2H), 
2.83 (s, 1H), 2.71 (t, J = 12.1 Hz, 2H), 1.85–1.97 (m, 2H), 1.55–1.72 (m, 6H), 1.38–1.51 (m, 
2H), 1.23–1.36  (m, 4H), 1.10–1.20 (m, 2H), 0.93 (s, 3H). LC/MS m/z: [M+H]+ calcd for 
C25H34N6, 419.3; found 419.5. 
 
6-(5,6-Dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-5-{1-[(1-methylcyclopentyl)methyl]-
1H-pyrazol-4-yl}pyridine-2-carbonitrile (25). Compound 25 was synthesized using the same 
approach described in Scheme 2. 1H NMR (500 MHz, DMSO-d6) δ 8.48 (s, 1H), 8.29 (s, 1H), 
8.01 (d, J = 7.7 Hz, 1H), 7.98 (s, 1H), 7.70 (d, J = 7.7 Hz, 1H), 4.46 (s, 2H), 4.08–4.13 (m, 2H), 
4.05 (s, 2H), 3.52–3.63 (m, 2H), 1.60 (s, 6H), 1.26 (s, 2H), 0.91 (s, 3H). LC/MS m/z: [M+H]+ 
calcd for C21H24N8, 389.2; found 389.5. 
 
3-Methyl-5-{1-[(1-methylcyclopentyl)methyl]-1H-pyrazol-4-yl}-6-(2-methyl-3-oxo-2,3-
dihydro-1H-isoindol-5-yl)pyridine-2-carbonitrile (26)  
Compound 43 (70 mg, 0.161 mmol), bis(tri-tert-butylphosphine)palladium(0) (8.22 mg, 0.016 
mmol) and  zinc cyanide (0.020 mL, 0.322 mmol) were dissolved in dioxane (1.5 mL) in a sealed 
tube. The reaction was heated at 180 °C under microwave irradiation for 15 min and the mixture 
was filtered and the solvent was removed  under reduced pressure. The residue was dissolved in 
EtOAc and washed with aqueous saturated NaHCO3, water, and brine. The organic layer was 
dried over anhydrous Na2SO4, filtered and concentrated. The material was purified by silica gel 
chromatography (5-100% EtOAc/hexanes) to give compound 26 (60 mg, 88%). 1H NMR (500 
MHz, CDCl3):  7.90 (s, 1H), 7.75 (s, 1H), 7.62 (d, J = 6.5 Hz, 1H), 7.49 (d, J = 8.0 Hz, 1H), 
 
7.39 (s, 1H), 6.94 (s, 1H), 4.45 (s, 2H), 3.90 (s, 2H), 3.24 (s, 3H), 2.66 (s, 3H), 1.20–1.80 (m, 
8H), 0.85 (s, 3H). LC/MS m/z: [M+H]+ calcd for C26H27N5O, 426.2; found 426.0. 
 
3-Chloro-5-{1-[(1-methylcyclopentyl)methyl]-1H-pyrazol-4-yl}-6-(2-methyl-3-oxo-2,3-
dihydro-1H-isoindol-5-yl)pyridine-2-carbonitrile (27). Compound 27 was synthesized using 
the same approach described in Scheme 3. Compound 27 was synthesized using the same 
approach described in Scheme 3. 1H NMR (400MHz, MeOD) δ 8.29 (s, 1H), 7.76 (s, 1H), 7.65–
7.70 (m, 2H), 7.46 (s, 1H), 7.26 (s, 1H), 4.58 (s, 2H), 3.91 (s, 2H), 3.22 (s, 3H), 1.55–1.70 (m, 
4H), 1.40–1.50 (m, 2H), 1.15–1.25 (m, 2H), 0.82 (s, 3H). LC/MS m/z: [M+H]+ calcd for 




Selectfluor (402 mg, 1.13 mmol) was added to a mixture of  compound 36 (310 mg, 1.03 mmol)  
in acetonitrile (5 ml) and the mixture was stirred at 180°C under microwave irradiation  for 30 
min. After cooling, the reaction mixture was concentrated.  The residue was purified by column 
chromatography on silica gel (ISCO 40 g gold), eluting with EtOAc/isohexane (2/1) to 
compound 44 (50 mg, 14% yield). LC/MS m/z: [M+H]+ calcd for C16H16ClFN4, 319.1; found 
319.0. 
A mixture of potassium  phosphate tribasic (30.0 mg, 0.14 mmol),[1,1′-
bis(diphenylphosphino)ferrocene]dichloropalladium(II) (1.9 mg, 2.4 µmol), compound 44 (15 
mg, 0.047 mmol) and compound 37 (19.0 mg, 0.071 mmol)  in 1,4-dioxane (2 ml) and water 
(0.25 ml) was degassed and purged with N2 7 times and the mixture was stirred at 110 °C under 
 
microwave irradiation for 1h. The reaction mixture was concentrated to dryness.  The residue 
was purified by column chromatography on silica gel (ISCO gold 40g), eluting with (hex/EA 
1/2)) to give compound 28 (14.5 mg, 72%).1H NMR (500 MHz, CDCl3) δ 7.86–7.93 (m, 2H), 
7.70 (d, J = 8.0 Hz, 1H), 7.67 (dd, J = 7.8, 1.6 Hz, 1H), 7.47 (d, J = 7.8 Hz, 1H), 7.02 (d, J = 2.9 
Hz, 1H), 4.40 (s, 2H), 3.80 (s, 2H), 3.20 (s, 3H), 1.56–1.70 (m, 4H), 1.45–1.54 (m, 2H), 1.25– 
1.34 (m, 2H), 0.89 (s, 3H). LC/MS m/z: [M+H]+ calcd for C25H24FN5O, 430.2; found 430.1. 
5-{5-Chloro-1-[(1-methylcyclopentyl)methyl]-1H-pyrazol-4-yl}-6-(2-methyl-3-oxo-2,3-
dihydro-1H-isoindol-5-yl)pyridine-2-carbonitrile (29) 
A mixture of NCS (98 mg, 0.73 mmol) and compound 36 (200 mg, 0.67 mmol) in  acetonitrile (4 
ml) was stirred at 100°C under microwave irradiation  for 30 min. The reaction mixture was 
concentrated. The residue was purified by column chromatography on silica gel (ISCO gold 80 
g), eluting with EtOAc/isohexane (15/1) to compound 45 (150 mg, 0.45 mmol, 67 %) as a 
colorless oil. 
A mixture of potassium  phosphate tribasic (57.0 mg, 0.268 mmol),[1,1′-
bis(diphenylphosphino)ferrocene]dichloropalladium(II) (3.65 mg, 4.47 µmol),  compound 45 (30 
mg, 0.089 mmol) and compound 37 (36.7 mg, 0.13 mmol)  in 1,4-dioxane (2 ml) and water (0.25 
ml) was degassed and purged with N2  7 times and the mixture was stirred at 110 °C under 
microwave irradiation for 1h. The reaction mixture was concentrated. The residue was purified 
by column chromatography on silica gel (ISCO gold 40g), eluting with (hex/EA 1/2)) to give 
compound 29 (32 mg, 80 %). 1H NMR (500 MHz, CDCl3) δ 7.92 (d, J = 7.9 Hz, 1H), 7.85 (s, 
1H), 7.72 (d, J = 7.9 Hz, 1H), 7.60 (dd, J = 7.8, 1.5 Hz, 1H), 7.40 (d, J = 7.8 Hz, 1H), 7.21 (s, 
1H), 4.38 (s, 2H), 3.98 (s, 2H), 3.19 (s, 3H), 1.51–1.74  (m, 6H), 1.27–1.37  (m, 2H), 0.90 (s, 
3H). LC/MS m/z: [M+H]+ calcd for C25H24ClN5O, 446.2; found 446.3. 
 
5-{5-Cyano-1-[(1-methylcyclopentyl)methyl]-1H-pyrazol-4-yl}-6-(2-methyl-3-oxo-2,3-
dihydro-1H-isoindol-5-yl)pyridine-2-carbonitrile (30)  
A mixture of compound 29 (11.4 mg, 0.026 mmol), dicyanozinc (9.0 mg, 0.077 mmol) and 
chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-
biphenyl)]palladium(II) (2.011 mg, 2.56 µmol)  in DMF (4 mL) was heated to 200 °C under 
microwave irradiation for 30 min. The crude reaction was concentrated and directly purified by 
column chromatography on silica gel (20:1 CH2Cl2/MeOH) to afford compound 30 (4.7 mg, 
42%). MS: 437 (M+1). 
1H NMR (500 MHz, CDCl3):  8.01 (d, J = 7.5 Hz, 1H), 7.80 (d, J = 8.0 
Hz, 1H) , 7.76 (dd, J = 7.5, 1.5 Hz, 1H), 7.73 (s, 1H), 7.54 (d, J = 8.0 Hz, 1H), 7.62 (dd, J = 8.0, 
1.5 Hz, 1H), 7.30 (s, 1H), 4.44 (s, 2H), 4.16 (s, 2H), 3.22 (s, 3H), 1.27–1.73 (m, 8 H), 0.95 (s, 
3H). LC/MS m/z: [M+H]+ calcd for C25H24FN5O, 437.2; found 437.4. 
 
5-{1-[(1-Methylcyclopentyl)methyl]-1H-pyrazol-4-yl}-6-(3-oxo-2,3-dihydro-1H-isoindol-5-
yl)pyridine-2-carbonitrile (40)  
Compound 36 (60 mg, 0.2 mmol), compound 39 (62 mg, 0.24 mmol), (1,1'-bis(di-tert-
butylphosphino)ferrocene palladium dichloride (10.42 mg, 0.016 mmol) and potassium 
phosphate tribasic (300 µl, 2 N aq. solution, 0.6 mmol) solution were added to a reaction tube 
with THF (1 mL).  The mixture was degassed three times before it was heated to  60 °C for 5 hr.  
After cooling, the reaction mixture was quenched by the addition of water (3 mL) and was 
partitioned with EtOAc (3 mL x 3). The combined organic layers were dried over anhydrous 
sodium sulfate and concentrated under reduced pressure. The crude material was purified with 
reverse phase HPLC, flow rate 50 mL/min using Sunfire C18 (19x150 mm column), mobile 
phase A, 0.1% NH4OH in H2O, mobile phase B, 0.1% NH4OH in acetonitrile, gradient, 16% to 
 
56% B, 25 mins run. Compound 40 (33 mg, 0.083 mmol, 45 %). 1H NMR (500 MHz, DMSO-
d6): δ 8.63 (s, 1H), 8.21 (d, J = 5.0 Hz, 1H), 8.05 (d, J = 5.0 Hz, 1H), 7.60–7.65  (m, 3H), 7.39 (s, 
1H), 7.32 (s, 1H), 4.43 (s, 2H), 3.86 (s, 2H), 1.46–1.57 (m, 4H), 1.37–1.41 (m, 2H), 1.10–1.15 
(m, 2H), 0.75 (s, 3H). 13C NMR (126 MHz, DMSO-d6): δ 169.9, 157.6, 144.9, 139.3, 138.4, 
138.4, 133.4, 132.5, 132.1, 131.3, 130.0, 128.4, 124.4, 123.8, 118.1, 117.7, 60.9, 45.4, 44.1, 37.1, 
24.9, 24.2. HRMS m/z: [M+H]+ calcd for C24H23N5O, 398.1981; found 398.1973. 
 
General Radiochemical Methods 
Detailed radiochemistry for labeled compounds will be described in a future publication.  
Briefly, a Siemens RDS-111 cyclotron was used to produce [11C]CO2 by the 
14N(p,α)11C reaction 
produced at PETNET Solutions (North Wales, PA). The resulting [11C]CO2 was converted to 
[11C]iodomethane ([11C]CH3I) using a TRACERlab FXc (GE Healthcare, Wauwatosa, WI).
 For 
all [11C]cyanation reactions, the [11C]CO2 was converted to [
11C]HCN using an Eckert & Ziegler 
Modular Lab apparatus (Berlin, Germany). Briefly, [11C]CO2 (1,500 mCi) from the target was 
trapped on molecular sieves at room temperature. The [11C]CO2 was released and mixed with 
hydrogen gas at 350 ºC then passed through a preheated nickel oven at 420 ºC for conversion to 
[11C]CH4. The [
11C]CH4 gas was purified by passing it through Ascarite and Sicapent columns to 
remove water and unreacted [11C]CO2. The [
11C]CH4 was mixed with anhydrous ammonia and 
passed through a high temperature (950 ºC) platinum oven, resulting in the formation of 
[11C]HCN (non-decay corrected radiochemical yields of 700-1000 mCi). Precursors were 
prepared at the Research Laboratories of Merck & Co., Inc. (Rahway, NJ, USA). The semi-
automated radiosynthesis of [11C] compounds were performed with a 233XL liquid handler 
(Gilson Inc., Middleton, WI) in a lead-shielded fume hood. The identity, specific activity, and 
 
radiochemical purity of [11C] compounds were determined using a Waters 600E HPLC, a Waters 
996 ultraviolet (PDA) detector (Waters, Milford, MA), and a FlowCount photodiode radio 
detector (Bioscan Inc., Washington D.C.). A Waters Xbridge C18 column (4.6x150 mm, 5 µm) 
with a mobile phase of acetonitrile and water. The products were purified using a Gemini C-18 
HPLC column (Phenomex, Torrance, CA) at a flow rate of 5 mL/min. 
 
Radiochemical Synthesis of [11C] Compounds 
Unless otherwise noted, this procedure was used for all [11C]CH3I reactions. [
11C]MeI (13 GBq) 
was trapped in a 0C mixture of precursor (0.2 mg, ~ 1μmol) in dimethylformamide (0.2 mL) 
and sodium hydroxide (1μL, 5 M). This mixture was transferred to a 2 mL v-vial preheated to 
50oC.  The reaction mixture was heated at 50C for 4 minutes, diluted with H2O (0.8 ml) and 
purified by HPLC (Phenomenex Gemini C18, 5 m, 100A, 10 × 150 mm) using 45:55 
acetonitrile:10 mM sodium phosphate at 5 mL/min, 20 mins run. The HPLC fraction containing 
[11C] compound (~ retention time ~10.2 min for [11C]2, ~12.1 min for [11C]13) was collected in a 
sterile glass vial. [11C]22 was synthesized by reaction of [11C]HCN (18 GBq) with bromo 
precursor 22 (1 mg, 2.27 µmol), triphenylphosphine palladium (2.4 mg, 2.0 µmol) and potassium 
bicarbonate (6 mg, 60 µmol) in an auto-sampler vial in dimethylformamide (0.3 ml) at 120 °C 
for 5 min. Subsequently, after cooling the crude reaction mixture to room temperature, 0.8 ml 10 
mM sodium phosphate was added, and the reaction mixture was purified by using the semi-
preparative HPLC method described above, Phenomenex Gemini C18 column (10x150 mm ,5 
µm), using 42:58 acetonitrile:10 mM sodium phosphate at 5 mL/min, 30 mins run. The peak 
corresponding to [11C]22 with retention time ~13.5 min was collected, diluted with saline and 
transferred to a sterile capped vial to provide [11C]22 injection solution. The final product was 
 
tested for chemical and radiochemical purity by means of an analytical HPLC system (Waters) 
using a Xbridge Phenyl 3.5μ4.6x150 mm column at a flow rate of 1 mL/min. For [11C]2, the 
mobile phase increased from 35:65 to 60:40 acetonitrile/Na2HPO4 (10 mM) using a 15-min 
linear gradient. [11C]13 and [11C]22, the mobile phase was acetonitrile / Na2HPO4 (10mM): 
42/58. Confirmation of the identity of the product was determined by coinjection of a sample of 
compound 2, or 13, or 22, and radiochemical purity (>98%) was determined using a sodium 
iodide detector (Bioscan). The retention times for compound [11C]2, [11C]13 and [11C]22 were 
10.3, 9.7, 9.9 min, respectively. 
 
In Vivo PET Imaging Studies in Rhesus Monkey 
The Research Laboratories of Merck & Co., Inc. obtained rhesus monkeys from Covance Inc. 
(Alice, TX), New Iberia Research Center (New Iberia, LA) and Mannheimer Foundation 
(Homestead, FL). All monkey PET imaging studies were conducted under the guiding principles 
of the American Physiological Society and the Guide for the Care and Use of Laboratory 
Animals published by the US National Institutes of Health (NIH publication No 85-23, revised 
2010) and were approved by the Research Laboratories of Merck & Co., Inc. (West Point, PA 
USA). Five rhesus monkeys (age range 5-9, ~ 7-10 kg, 2 males and 3 females) were initially 
sedated with ketamine (10 mg/kg, IM), then induced with propofol (5 mg/kg, IV), intubated, and 
respired with medical grade air and oxygen mixture at ~10 ml.breath-1kg-1 and 23 respirations 
per minute. The anesthesia was maintained with propofol (0.4-0.55 mg.kg-1.min-1) for the 
duration of the study. Body temperature was maintained with circulating water heating pads, and 
temperature, oxygen saturation, blood pressure, and end-tidal CO2 were monitored for the 
 
duration of the study. Dynamic PET scans were acquired by Imaging laboratory at the Research 
Laboratories of Merck & Co., Inc. (West Point, PA, USA) in PET/CT or HR+ scanner (Siemens) 
for 90 min following a 2-min bolus IV injection of [11C]compound (~185 MBq, <2 g).  Frame 
durations were ranged from 15 s to 10 min. PET images were corrected for attenuation and 
scatter. PET scans were co-registered to standard template space with or without 
subject/template MRI to define the regional uptake. Regional time activity curves were drawn on 
the PET images to quantify the regional tracer uptake in terms of peak standard uptake value 
(SUV), area under the curve (AUC) or SUV ratio of target and reference regions. Based on prior 
autoradiography and saturation binding studies cerebellum has minimal M4 receptors, and 
therefore cerebellum was used as reference region for simplified reference tissue model (SRTM). 
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